Roche, a top big pharma and big biotech company and AREVA Med have entered into a strategic pharma partnering collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells.
The pharma partnering agreement will focus on malignant disease with a high unmet medical need.
Under this exclusive pharma partnering agreement, Roche’s Pharma Research and Early Development organization and AREVA Med will assess the efficacy of combining Roche-engineered antibodies with AREVA Med’s radionuclide, Lead-212, a compound that shows promise in treating some types of cancer.
Roche retains exclusive rights to commercialise the cancer radio-immunotherapy after clinical development.
Alpha radio-immunotherapy is a novel cancer treatment with several advantages over conventional radiotherapy.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity